News from Neuronasal
June, 2026
Proof of Concept study started for GLP-1 + NAC. This research will determine if their is synergy between GLP-1 and NAC at the cellular level.
June, 2026
Proof of Concept study started for GLP-1 molecules linked with “Trojan Horse.” This research will measure brain delivery of the new GLP-1 compounds in comparison with the “native” GLP-1s.
May, 2026
Cellular test data shows positive results in increased affinity of GLP-1 molecules linked with “Trojan Horse.” This early research provide good support the follow-on Proof of concept study.
April, 2026
US Patent 12,594,254 issued. “Intranasal Administration of N-acetylcysteine combined with other medicaments.” This wide-ranging patent opens the door to unlimited combinations with IN NAC and other drugs using any route of administration.
October, 2024
STTR NIH/NIA grant award to Neuronasal to conduct Phase 1 clinical dose finding research.
September, 2024
US Patent 12,090,130. Issued. Method of Treating Brain Disorders
April, 2024
US Patent. 11,963,939 issued. Use of N-acetylcysteine to Treat Central Nervous System Disorders
May, 2023
US Patent 11,660,278 issued. Use of N-acetylcysteine to Treat Central Nervous System Disorders.
November, 2022
Neuronasal received from the USPTO notice of allowance on its core patent application US 16/700,588 Use of N-acetylcysteine to treat CNS Diseases.
May, 2022
Review and validation of the MRS of human pilot study by world leading MRS group at John Hopkins Medical School
January, 2022
October, 2021
January, 2021
September 23, 2020
Press Release ATAI collaboration:
FDA approves Neuronasal IND.
Today, ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, and Neuronasal announced the completion of a pilot study intended to show nose to brain delivery of N-acetylcysteine (NAC) in healthy volunteers. Additionally, Neuronasal has been granted Investigational New Drug (IND) clearance by the FDA to continue phase I clinical trial development with ATAI’s support. Continue to read
June, 2020
Neuronasal received regulatory approval to start human pilot trial demonstrating nose to brain drug delivery.
December, 2019
ATAI Life Sciences announced an investment in Neuronasal Inc. To support the development of a treatment for concussion. Matthias Luz, MD and Greg Bates, PhD both of ATAI Life joined the Neuronasal board of directors as part of this investment.
A copy of the press release from both companies is available at
https://www.fiercebiotech.com/biotech/atai-backs-neuronasal-s-through-nose-concussion-treatment.
June 3-6, 2019
Neuronasal has been selected as a finalist for Startup Stadium and will present at BIO in Philadelphia.
May 8, 2019
Neuronasal has been selected to present at BioNJ at the Palace in Somerset, New Jersey.
January 7-10,2019
Neuronasal is participating J.P. Morgan 37th Annual healthcare Conference
June 4, 2018
Neuronasal is participating in RESI and BIO in Boston.
May 3, 2018
Neuronasal jointly filed broad US patent with Weill Cornell Medical School claiming FLAP inhibitors to treat brain injury and the delivery of FLAP inhibitors, including NAC, intranasally to treat brain injury including concussion.
April, 2017
Rajiv Ratan,MD PhD, chairman of Neuronasal Science Advisory Board and Director of the Burke Research Institute Weill Cornell Medical School co authored Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis in Stroke